ES2058602T3 - Preparados del oxipurinol y/o de sales de metales alcalinos o alcalinoterreos. - Google Patents

Preparados del oxipurinol y/o de sales de metales alcalinos o alcalinoterreos.

Info

Publication number
ES2058602T3
ES2058602T3 ES89912952T ES89912952T ES2058602T3 ES 2058602 T3 ES2058602 T3 ES 2058602T3 ES 89912952 T ES89912952 T ES 89912952T ES 89912952 T ES89912952 T ES 89912952T ES 2058602 T3 ES2058602 T3 ES 2058602T3
Authority
ES
Spain
Prior art keywords
alkaline
oxipurinol
salts
prepared
terrain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89912952T
Other languages
English (en)
Inventor
Wolfgang Lahr
Guido Weickgenannt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henning Berlin GmbH Chemie- und Pharmawerk
Original Assignee
Henning Berlin GmbH Chemie- und Pharmawerk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henning Berlin GmbH Chemie- und Pharmawerk filed Critical Henning Berlin GmbH Chemie- und Pharmawerk
Application granted granted Critical
Publication of ES2058602T3 publication Critical patent/ES2058602T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LAS PREPARACIONES DE OXIPURINOL Y/O DE SUS SALES DE ALCALI O DE ALCALITERREO EN UNA FORMA NO CRISTALIZADA CONTIENEN ACTIVADORES EN FORMA DE UNA DISPERSION DE MATERIA FIJA CON SUSTANCIAS AUXILIARES NO PENSADAS FARMACOLOGICAMENTE. TIENEN UNA ALTA Y RAPIDA SOLUBILIDAD SOBRE EL OXIPURINOL Y/O SUS SALES DE ALCALI O DE ALCALITERREO. SE PUEDEN UTILIZAR PARA LA ELABORACION DE MEDICAMENTOS CON UN ALTO GRADO DE LA SUSTANCIA OXIPURINOL.
ES89912952T 1988-11-25 1989-11-24 Preparados del oxipurinol y/o de sales de metales alcalinos o alcalinoterreos. Expired - Lifetime ES2058602T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3839825A DE3839825A1 (de) 1988-11-25 1988-11-25 Feststoffdispersionen enthaltend oxipurinol und/oder seine alkali- oder erdalkalisalze

Publications (1)

Publication Number Publication Date
ES2058602T3 true ES2058602T3 (es) 1994-11-01

Family

ID=6367881

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89912952T Expired - Lifetime ES2058602T3 (es) 1988-11-25 1989-11-24 Preparados del oxipurinol y/o de sales de metales alcalinos o alcalinoterreos.

Country Status (5)

Country Link
EP (1) EP0445158B1 (es)
JP (1) JP2965689B2 (es)
DE (2) DE3839825A1 (es)
ES (1) ES2058602T3 (es)
WO (1) WO1990006115A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671811B2 (en) * 1991-12-18 1996-09-12 Warner-Lambert Company A process for the preparation of a solid dispersion
DE4406462C2 (de) * 1994-02-24 1997-05-28 Jenapharm Gmbh Verfahren und Vorrichtung zur Herstellung fester Dispersionen
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE10000792A1 (de) 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2009118356A2 (en) * 2008-03-25 2009-10-01 Formac Pharmaceuticals N.V. Preparation method for solid disupersions
WO2016010093A1 (ja) * 2014-07-16 2016-01-21 株式会社セラバリューズ 非晶質クルクミン及び／又はその類縁体を含有する複合体の製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB975850A (en) * 1955-08-10 1964-11-18 Wellcome Found Xanthine oxidase inhibitors
GB1460302A (en) * 1973-05-23 1977-01-06 Wellcome Found Tablet formulation
DE2546371A1 (de) * 1975-10-16 1977-04-21 Sandoz Ag Neue galenische formen
ZA871813B (en) * 1986-03-13 1988-10-26 Wellcome Found Cell protection

Also Published As

Publication number Publication date
EP0445158A1 (de) 1991-09-11
EP0445158B1 (de) 1993-08-04
JP2965689B2 (ja) 1999-10-18
WO1990006115A3 (de) 1990-08-23
DE3839825A1 (de) 1990-06-13
DE58905187D1 (de) 1993-09-09
JPH04502004A (ja) 1992-04-09
WO1990006115A2 (de) 1990-06-14
DE3839825C2 (es) 1992-04-16

Similar Documents

Publication Publication Date Title
ES2098180B1 (es) Una composicion farmaceutica a base de compuestos de la clase de la rapamicina.
MX9302834A (es) Aplicador de aguja hueca.
ES2058602T3 (es) Preparados del oxipurinol y/o de sales de metales alcalinos o alcalinoterreos.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
ATE106719T1 (de) Arzneimittel mit gesteuerter wirkstoffreisetzung.
IT1148238B (it) Dispositivo per la somministrazione di medicamenti in polvere
DE3780222D1 (de) Pharmazeutische zusammensetzung mit kontrollierter wirkstofffreisetzung.
MX9405219A (es) Nueva formulacion farmaceutica.
AR242711A1 (es) Pelicula laminada bicomponente, el proceso para obtenerla y el articulo absorbente desechable que la incluye.
AR019855A1 (es) Uso de conjugados de peg-ifn-alfa y ribavirina para la fabricacion de un medicamento para el tratamiento de hepatitis c cronica
DE69101931D1 (de) Pharmazeutische Zusammensetzung.
IT8820127A0 (it) Impiego di derivati dei perfluoropolieteri in forma di microemulsione acquosa per la protezione dei materiali lapidei dagli agenti atmosferici.
DE69126270D1 (de) Transdermale therapeutische Zubereitungen
DE69310887D1 (de) Pharmazeutische behälter und medizinische geräte mit hydrophilen, proteinverträglichen oberflächen
ITRM910402A0 (it) Articolo contenente medicamento e dispositivo di erogazione per esso.
DE3882157D1 (de) Nichtsteroide antientzuendungswirkstoffe enthaltende pharmazeutische zubereitungen.
ES2179533T3 (es) Formulacion de medicamento con liberacion controlada del principio activo.
ES1007668Y (es) Dispositivo con al menos un recipiente para la conservacion y entraga de una sustancia.
MX9206311A (es) Bolsas usadas para almacenar y/o transportar material.
AR242907A1 (es) Dispositivo de doble punta para dosificar y suministrar medicamentos.
USD300836S (en) Shelf clip for holding promotional advertising materials
USD246148S (en) Dispensing rack for contact lens vials
DE69012031D1 (de) Optisch aktive Benzylalkoholverbindung und pharmazeutische Zusammensetzung.
AR012996A1 (es) Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.
IT1231342B (it) Derivati peptidici farmacologicamente attivi e preparazioni farmaceutiche che li contengono

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 445158

Country of ref document: ES